Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume – Here’s What Happened

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) saw unusually-high trading volume on Tuesday . 719,539 shares were traded during mid-day trading, an increase of 32% from the previous session’s volume of 543,220 shares.The stock last traded at $14.14 and had previously closed at $14.35.

Silence Therapeutics News Summary

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: HC Wainwright raised most of its earnings forecasts for Silence Therapeutics, including FY2026 EPS to $(1.14) from $(1.38), FY2027 EPS to $(1.38) from $(1.74), FY2028 EPS to $(1.53) from $(1.65), and FY2030 EPS to $(1.50) from $(1.77). The firm also improved estimates for each quarter from Q3 2026 through Q4 2027, indicating expectations for narrower losses than previously projected.
• Positive Sentiment: HC Wainwright maintained its Buy rating and $75 price target. With SLN recently trading near $14, the target implies substantial potential upside if the company meets the analyst’s longer-term expectations.
• Positive Sentiment: Unusual options activity added a bullish signal: investors purchased 24,155 call options, compared with average daily call volume of 555. Heavy call buying can indicate expectations for additional share-price gains, although it is not confirmation of future performance.
• Neutral Sentiment: Silence Therapeutics is still expected to report losses, with consensus full-year EPS at $(1.08) and HC Wainwright forecasting $(1.14) for FY2026. The revised estimates represent improving loss expectations rather than near-term profitability.
• Negative Sentiment: HC Wainwright lowered its FY2029 EPS forecast to $(1.92) from $(1.74), showing that the long-term outlook is not uniformly improving. The company also recently missed quarterly EPS expectations, underscoring execution and valuation risk.

Analyst Ratings Changes

Several research analysts have commented on SLN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald initiated coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating on the stock. Morgan Stanley raised their price target on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Silence Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $53.50.

Silence Therapeutics Stock Performance

The firm has a market capitalization of $659.57 million, a PE ratio of -10.90 and a beta of 1.39. The stock has a fifty day moving average price of $10.26 and a 200-day moving average price of $7.55.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. Research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Silence Therapeutics by 18.1% in the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock valued at $121,000 after buying an additional 1,698 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $71,000. China Universal Asset Management Co. Ltd. lifted its position in Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after acquiring an additional 5,421 shares during the last quarter. Massar Capital Management LP purchased a new stake in Silence Therapeutics during the second quarter valued at approximately $115,000. Finally, Citadel Advisors LLC acquired a new stake in Silence Therapeutics in the third quarter valued at approximately $112,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.